Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer.

ABSTRACT:

Purpose

Circular RNA (circRNA) has emerged as a promising RNA therapeutic molecule due to its enhanced stability and prolonged protein expression compared to messenger RNA (mRNA). Using circRNA to construct transient Chimeric Antigen Receptor (CAR)-T cells can mitigate the limitations of conventional viral vector-based CAR-T approaches, such as complex process and long-term side effects.

Methods

The study first reconfirmed the advantageous properties of circRNA, focusing on its stability and protein expression efficiency. Electroporation conditions were then optimized for the efficient delivery of circRNA into human primary T cells. Subsequently, a circRNA encoding the anti-Delta-like Ligand 3 (DLL3) CAR was constructed, and CAR-T cells were generated via electroporation. Th

SUBMITTER: Cai J 

PROVIDER: S-EPMC11905684 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature